Back to Journals » Journal of Pain Research » Volume 17
Efficacy and Safety of Rimegepant 75 Mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial [Corrigendum]
Lipton RB, Thiry A, Morris BA, Croop R. J Pain Res. 2024 Jul 22:17:2431–2441.
The authors have advised that Figure 2 on page 2437 is incorrect. The text “150/241 (27.7%)” in the Placebo n/N (Risk) column for the row Freedom from MBS at 2 hours in the Coprimary section should read “150/541 (27.7%)”.
The correct Figure 2 is shown below.
 |
Figure 2 Forest plot of coprimary and secondary efficacy endpoints for mITT participants. Abbreviations: mITT, modified intent-to-treat; CI, confidence interval; MBS, most bothersome symptom. Notes: Risks were stratified by use of preventive migraine medication using Mantel–Haenszel risk estimation. Secondary efficacy endpoints are listed in the order specified in the endpoint testing hierarchy. aStatistically significant in hierarchical testing, P<0.05. bStatistically significant in hierarchical testing, P<0.005. cStatistically significant in hierarchical testing, P<0.001. dDirection reversed so that positive risk difference favors rimegepant. |
The authors apologize for this oversight.
© 2024 The Author(s). This work is published and licensed by Dove Medical Press Limited. The
full terms of this license are available at https://www.dovepress.com/terms
and incorporate the Creative Commons Attribution
- Non Commercial (unported, 3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted
without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.